Mars rover technology tested out in Scottish Highlands
A team from the University of St Andrews has been testing equipment in Lower Diabaig in Torridon, where there are rocks that are billions of years old and similar to those found on Mars.
The European Space Agency (ESA) is planning to send a robotic rover to Mars to study its geology and look for fossils and minerals, the BBC reports.
So far, the trials in Torridon have considered the type of cameras which should be used as the rover's "eyes", as well as tests on equipment that can detect ancient biology preserved in the rock.
READ MORE: Update as huge wildfire continues to burn in West Lothian amid 'extreme warning'
The robot is named after London-born scientist Rosalind Franklin, who died in 1958.
ESA said the missions would tackle the question of whether life has ever existed on Mars.
The project, known as the ExoMars programme, is made up of two missions. The First, called Trace Gas Orbiter, was launched in 2016. The second mission has a target launch of 2028 and aims to land the rover on Mars.
Many geological areas and features on Mars have been named by Nasa after places on Earth, including in Scotland.
Some of the names taken from Scotland include Torridon, Holyrood, Siccar Point, Muck, Wick and Sandwick.
Dr Claire Cousins, from the University of St Andrews, said the rare geology around Lower Diabaig was "ideal" for testing the rover.
READ MORE: I visited Donald Trump's ancestral homeland. This is what I learned about him
She told BBC Scotland's Landward programme: "The rocks haven't metamorphosed right, they haven't been cooked and squeezed and crushed under mountain belts.
"They have been beautifully preserved – a slice of time.
"We don't know yet if there was ever life on Mars, but these are the kinds of rocks that are going to preserve it."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
12 hours ago
- The Sun
Three-drug treatment combo ‘holds back aggressive breast cancer for a year'
A NEW triple threat drug combination could hold aggressive breast cancer at bay for an extra year, a trial found. Adding the medicine inavolisib to an already used pair of drugs delayed the need for chemotherapy by almost two years. 1 It prevented tumours from growing for an average of 17 months, compared to seven months in patients using the standard drug pairing palbociclib and fulvestrant. An estimated 1,000 British women per year could benefit. The combo works for women with a specific breast cancer type called HR+ HER2- with a PIK3CA mutation, which accounts for about three in 10 cases. Professor Kristian Helin, chief of The Institute of Cancer Research in London, said: 'We need to tackle treatment resistance head-on to continue improving survival rates. 'This triple combination approach effectively shuts down cancer's escape routes, giving people with metastatic breast cancer the opportunity to live well for longer.' The trial included 325 patients with aggressive and advanced breast cancer from 28 countries. Cancers shrank in two thirds of people receiving the triple drug combination, compared to 28 per cent of those on standard treatment. New go-to option for docs Study author Professor Nicholas Turner, of the Royal Marsden NHS hospital in London, said: 'This therapy not only helped patients live longer but it more than doubled the time before their cancer progressed or worsened. 'It also gave them more time before needing chemotherapy which is something that patients really fear and want to delay for as long as possible.' 'These results give us confidence that this treatment could become the new go-to option.' The study was presented at the conference of the American Society of Clinical Oncology. What are the signs of breast cancer? BREAST cancer is the most common type of cancer in the UK. The majority of women who get it are over 50, but younger women and, in rare cases, men can also get breast cancer. If it's treated early enough, breast cancer can be prevented from spreading to other parts of the body. Breast cancer can have a number of symptoms, but the first noticeable symptom is usually a lump or area of thickened breast tissue. Most breast lumps aren't cancerous, but it's always best to have them checked by your doctor. You should also speak to your GP if you notice any of the following: a change in the size or shape of one or both breasts discharge from either of your nipples (which may be streaked with blood) a lump or swelling in either of your armpits dimpling on the skin of your breasts a rash on or around your nipple a change in the appearance of your nipple, such as becoming sunken into your breast Source: NHS
Sky News
17 hours ago
- Sky News
'Transformational' new drug could stop breast cancer tumours before they grow, trial finds
A new drug could stop some breast cancer tumours from using hormones to grow, a trial has found. Results from the Serena-6 trial, carried out with the Institute of Cancer Research in London, suggest that using camizestrant could help patients stay well longer and delay the need for chemotherapy. According to Cancer Research UK, the drug works by blocking oestrogen from getting into the breast cancer cell, which researchers hope can then stop or slow the growth of cancer. Breast cancer patients given the drug in the trial reduced their chances of the disease progressing by 52% compared to standard therapies. Professor Kristian Helin, chief executive of the Institute of Cancer Research, said the results "represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine". Co-principal investigator Professor Nick Turner also called the development of the drug "a pivotal moment in breast cancer care". 1:48 The study, funded by AstraZeneca, looked at patients with hormone-positive, HER2-negative breast cancer - about 70% of cases. More than 3,000 patients from 23 countries took part in phase three of the trial, which saw doctors use blood tests to detect changes in the cancer's DNA to see which treatments were ineffective. For those taking camizestrant, their cancer stabilised for around 16 months on average, compared with about nine months for other treatments. However, 1% of patients taking the new drug stopped taking it because of side effects. Further results from the Serena-6 trial will be presented at the American Society of Clinical Oncology annual meeting in Chicago on Sunday. Cancer Research UK reports that breast cancer is the most common type of the disease, with around 56,400 women and around 390 men diagnosed in the UK each year. The trial was also the first worldwide study to show that using blood tests to find early signs of cancer resistance to treatment helps patients. Dr Catherine Elliott, director of research at Cancer Research UK, praised the breakthrough as a "clear example of how blood tests are starting to transform cancer treatment". "By tracking tiny traces of tumour DNA in the blood, researchers were able to spot early signs of treatment resistance and switch therapies before cancer had a chance to grow," she added. "It shows how circulating tumour DNA, or ctDNA, could help doctors make smarter, more timely treatment decisions. "This approach could become an important part of how we personalise care for people with advanced breast cancer."
Belfast Telegraph
a day ago
- Belfast Telegraph
Strauss's Blue Danube beamed into space as Vienna celebrates with concert
The European Space Agency's big radio antenna in Spain beamed the waltz into the cosmos on Saturday. Operators aimed the dish at Voyager 1, the world's most distant spacecraft, more than 15 billion miles away. Travelling at the speed of light, the music was expected to overtake Voyager 1 within 23 hours. The Vienna Symphony Orchestra performed the Blue Danube during the space transmission, which actually sent up a version from rehearsal. It is part of a year-long celebration marking the 200th birthday of Johann Strauss, who was born in Vienna in 1825. The Strauss space send-off also marks the 50th anniversary of ESA's founding. Launched in 1977 and now in interstellar space, each of the two Voyagers carries a Golden Record full of music but nothing from Strauss. His Blue Danube holds special meaning for space fans, as it is featured in Stanley Kubrick's 1968 sci-fi film 2001: A Space Odyssey.
